baber/WOPTO huggingface dataset:
Patent NZ-550357-A (NZ)
Title: Safety measure for a pitched roof
Inventor: BORRA HANS ANTONIUS
IPC: E04G5/04
Filed: 2005-04-05
Abstract: A safety measure for accessing a pitched roof is disclosed. A belt provided with loops for anchoring a person who accesses the roof is proposed. This belt is permanently installed on the roof slab and under the horizontal battens that support the roof elements, such as tiles. After removing one or more tiles, the belt, and more particularly the loops thereof, is exposed and a safety measure can be provided.
Patent NZ-553749-A (NZ)
Title: Methods and apparatuses for thermal treatment of foods and other biomaterials, and products obtained thereby
Inventor: SWARTZEL KENNETH R
IPC: A23L19/12
Filed: 2005-11-14
Abstract: A process for thermally treating a flowable material while passing the flowable material, as a continuous stream, through a thermal treatment apparatus, is disclosed. The process includes: (a) passing a semi-solid flowable material continuously through a conduit, where at least a portion of the conduit is transparent to electromagnetic radiation; (b) heating the flowable material by exposing a portion of the conduit, transparent to electromagnetic radiation, to a source of electromagnetic radiation; and (c) mixing the flowable material within the conduit to provide for thermal equalization in the flowable material.
Patent NZ-554278-A (NZ)
Title: Fermented milk or vegetable proteins comprising receoptor ligand and uses thereof
Inventor: FLAMBARD BENEDICTE
IPC: A61K35/20
Filed: 2005-09-05
Abstract: Provided is the use of a composition obtained by a process comprising fermenting a food material, which comprises animal milk, with at least one lactic acid bacterial strain to obtain a fermented food or feed material comprising at least one component that is a ligand of an adrenergic or a serotonin receptor for the manufacture of a product for treatment or prevention of benign prostate hypertrophy (BPH) and/or erectile dysfunction in a mammal. The product can be used in addition in the manufacture of a medicament for reducing heart rate, treatment or relief of heart diseases, chronic renal failure and other diseases.
Patent NZ-563044-A (NZ)
Title: Multi-carrier operation in data transmission systems
Inventor: MALLADDI DURGA PRASAD
IPC: H04L12/70
Filed: 2006-04-21
Abstract: A method of operating a base transceiver station in a radio network includes the steps of: transmitting at least one downlink anchor carrier with a first common channel; and transmitting at least one downlink non-anchor carrier that does not carry the first common channel, the step of transmitting at least one downlink non-anchor carrier overlapping in time with the step of transmitting at least one downlink anchor carrier. Also disclosed is a base transceiver station in a radio network. The base transceiver station includes means for transmitting data to user equipment devices on a plurality of downlink carriers. The means for transmitting is configured to transmit at least one downlink anchor carrier with a first common channel, and transmit at least one downlink non-anchor carrier that does not carry the first common channel; transmissions of the at least one downlink anchor carrier overlapping in time with transmissions of the at least one downlink non-anchor carrier. Also disclosed is a method of operating a user equipment device in a radio network including the steps of: receiving from a base transceiver station of the radio network at least one downlink anchor carrier with a first common channel; acquiring radio network system using the at least one downlink anchor carrier; and receiving payload data on at least one downlink non-anchor carrier that does not carry the first common channel, the step of receiving payload data overlapping in time with the step of receiving at least one downlink anchor carrier. Also disclosed is a wireless user equipment device for communicating with a radio network including: means for receiving downlink carriers; and means for controlling arranged to configure the means for receiving to receive from a base transceiver station of the radio network at least one downlink anchor carrier with a first common channel, acquire radio network system using the at least one downlink anchor carrier, and configure the means for receiving to receive payload data on at least one downlink non-anchor carrier that does not carry the first common channel at the same time as receiving the at least one downlink anchor carrier.
Patent NZ-565541-A (NZ)
Title: Wireless relay for payment enforcement devices and method of using same
Inventor: SIMON MICHAEL P
IPC: B60R25/04
Filed: 2004-07-09
Abstract: A system for disabling a vehicle, which has a critical system, is disclosed. The system comprises a vehicle disablement device that includes a wireless transmitter, where the vehicle disablement device is configured to disable the critical system of the vehicle if a payment is not made on the vehicle prior to a payment due date. A disablement of the critical system prevents operation of the vehicle by transmitting a wireless disablement signal to a relay in a power control panel, and the relay disables power to the critical system in response to the wireless disablement signal.
Patent NZ-568860-A (NZ)
Title: Protein kinase modulation by hops and acacia products
Inventor: TRIPP MATTHEW L
IPC: A61K38/43
Filed: 2006-12-11
Abstract: Disclosed is the use of a composition in the manufacture of a medicament for treating a disease or disorder responsive to modulation of the activity of a protein kinase in a subject in need thereof, wherein said composition comprises (i) a reduced isoalpha acid, and (ii) a component or extract derived from Acacia; wherein a. said protein kinase is selected from the group consisting of ABL, AKT, AMPK, AURORA, BTK, CAMK, CDK, CHK, CSK, DBF2/20,EGFR, EPH/ELK/ECK, ERK/MAPKFGFR, GSK3, IGF-IR, IKKB, INSR, JAK DOM 1/2, MARK/PRKAA, MEK/STE7, MEKK/STE 11, MLK, mTOR, PAK/STE20, PDGFR, PI3K, PKC, POLO, SRC, TEC/ATK, and ZAP/SYK; b. the reduced isoalpha acid is selected from the group consisting of dihydro-isohumulone, dihydro-isocohumulone, dihydroisoadhumulone, tetrahydro-isohumulone, tetrahydro-isocohumulone, tetrahydro-isoadhumulone, hexahydro-isohumulone, hexahydroisocohumulone, hexahydro-isoadhumulone, and rho-isoalpha acids; and c. the component or extract derived from Acacia is derived from Acacia catechu or Acacia nilotica.
Patent NZ-568867-A (NZ)
Title: Compositions providing tolerance to multiple herbicides and methods of use thereof
Inventor: MCCUTCHEN BILLY FRED
IPC: A63B/
Filed: 2006-08-22
Abstract: Provided is a monocot transgenic plant or a monocot transgenic plant cell comprising a polynucleotide encoding a glyphosate-N-acetyltransferase polypeptide, wherein said polynucleotide is operably linked to (a) a promoter that drives expression in the monocot plant and (b) at least one copy of an enhancer sequence comprising a specified nucleotide sequence, wherein said enhancer sequence modulates the level of transcription, wherein said enhancer is heterologous to said promoter and, wherein said monocot plant or monocot plant cell is tolerant to glyphosate applied at a level effective to inhibit the growth of a control plant which does not comprise said polynucleotide encoding said glyphosate-N-acetyltransferase. Further provided are an expression cassette comprising said polynucleotide and a method of improving transformation efficiency comprising introducing said polynucleotide into monocot plant or plant cell, contacting said plant or cell with glycophosphate and selecting said plant or cell based on expression of said polynucleotide.
Patent NZ-573735-A (NZ)
Title: Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives
Inventor: JI JIANGUO
IPC: C07D451/08
Filed: 2007-05-15
Abstract: Disclosed is the aza-bicyclo[3.2.1]oct-3-yloxy compound of formula (I) or a pharmaceutically acceptable salt, ester or amide thereof, wherein n is 1, 2 or 3; A is N or N+-O-; R is hydrogen, alkyl, cycloalkylalkyl and arylallcyl; L is selected from the group consisting of O, S, and -N(Ra)-; Ar1 is a 6-membered 6 membered ring; and Ar2 is a fused nine-membered bicyclic heteroaryl; and Ra is selected from the group consisting of hydrogen, alkyl and alkylcarbonyl for treating or preventing a condition or disorder selected from the group consisting of attention deficit disorder, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, Pick's Disease, dementia associated with Lewy bodies, dementia associated with Down's syndrome, arnyotrophic lateral sclerosis, Huntington's disease, diminished CNS function associated with traumatic brain injury, acute pain, post-surgical pain, chronic pain, inflammation, inflammatory pain, neuropathic pain, infertility, need for new blood vessel growth associated with wound healing, need for new blood vessel growth associated with vascularization of skin grafts, and lack of circulation, rheumatoid arthritis, Crohn's disease, ulcerative colitis, inflammatory bowel disease, organ transplant rejection, acute immune disease associated with organ transplantation, chronic immune disease associated with organ transplantation, septic shock, toxic shock syndrome, sepsis syndrome, depression, and rheumatoid spondylitis.
Patent NZ-574516-A (NZ)
Title: Flow controller with dial to adjust cam to compress conduit
Inventor: AVERY RAYMOND JOHN
Filed: 2006-12-22
Abstract: Disclosed is a flow controller including a clamp to compress a conduit against a compression surface, and a dial to adjust the flow rate by driving a cam, separately formed from the clamp, so as to adjust the compression of the conduit and thus the flow rate.
Patent NZ-575638-A (NZ)
Title: Improvements relating to tubular members and/or conduits and/or methods and/or assemblies for joining tubular members
Inventor: KRAMER MICHAEL ROBERT
IPC: B23K1/00
Filed: 2009-03-18
Abstract: A method of joining together tubular members which are substantially comprised of non-corrosion resistant material so as to provide a substantially corrosion-resistant joint by welding, the method comprising the steps of welding a first corrosion-resistant tubular member or sleeve 24 to a first non-corrosion resistant tubular member, so as to form a first corrosion-resistant end piece 27 having a first corrosion-resistant open end, welding a second corrosion-resistant tubular member or sleeve 22 to a second non corrosion-resistant tubular member, so as to form a second corrosion-resistant end piece 26 having a second corrosion-resistant open end, applying a corrosion-protective coating to both the non-corrosion resistant tubular members, positioning the first and second open ends in substantial axial alignment with each other so that the first corrosion resistant end-piece is in contact with the second corrosion-resistant end-piece but not with the second non-corrosion-resistant tubular member and the second corrosion-resistant end-piece is not in contact with the first non-corrosion resistant tubular member, and externally welding the first and second corrosion-resistant end-pieces together using corrosion-resistant welding material 29.
Patent NZ-576421-A (NZ)
Title: Hydrogen generation apparatus comprising a reaction vessel, water supplying part, a hydrogen purifying part and a hydrogen storing part
Inventor: PARK JUNG-TAE
IPC: C01B3/08
Filed: 2008-03-10
Abstract: A composition when used for generating hydrogen gas. The composition includes 40-70 weight % of calcium oxide (CaO) powder; 2-20 weight % of calcium chloride (CaCl2), magnesium chloride (MgCl2) or sodium bicarbonate (NaHCO3) powder; 6.7-30 weight % of aluminium or alumina (Al2O3) powder; and 0.001-10 weight % of iron or magnesium powder.
Patent NZ-587132-A (NZ)
Title: Anti-cd79b antibodies and immunoconjugates and methods of use
Inventor: CHEN YVONNE
IPC: A61K39/395
Filed: 2009-01-14
Abstract: Provided is a cysteine engineered anti-CD79b antibody comprising one or more free cysteine amino acids and a sequence selected from VTVSSCSTKGP and GLSSPCTKSFN. The antibodies are useful for making antibody-drug conjugates for the treatment of treating various tumours and cancers.
Patent NZ-587450-A (NZ)
Title: Water-bearing domestic appliance with at least one water diverter for distributing washing liquor
Inventor: BUSING JOHANNES
IPC: D06F39/08
Filed: 2009-03-24
Abstract: 587450 Disclosed is a water-bearing domestic appliance, in particular a dishwashing machine or washing machine, comprising at least one water diverter for distributing washing liquor, the diverter comprising at least one carrier element (29) with an actuator (23) fastened thereto. The carrier element (29) is a cast part with line means embedded therein for actuating the actuator (23). The carrier element is produced using a plastic injection moulding method.
Patent NZ-589812-A (NZ)
Title: Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof
Inventor: ZOLLINGER WENDELL DAVID
IPC: A61K39/116
Filed: 2009-06-01
Abstract: Disclosed is a vaccine comprising native outer membrane vesicles (NOMVs) obtained from at least two meningococcal strains that have been genetically modified to provide broad based protection, wherein the native outer membrane vesicles include different sets of antigens, wherein the different sets of antigens comprise one or more PorA proteins, one or more LOS, and one or more conserved outer membrane proteins; wherein the genetically modified strains have been modified to provide enhanced safety based on inactivation of lpxL1, synX, and IgtA genes; and wherein at least one of the genetically modified strains expresses at least two different PorA subtype proteins or subtype epitopes. Further disclosed is a genetically modified vaccine strain of Neisseria meningitidis subtype B comprising the genetic modifications of: i) inactivation of a synX gene, ii) inactivation of the lpxL1 gene, iii) inactivation of the lgetA gene, iv) insertion of a second porA gene in the place of a opaD gene, v) increased expression of NadA compared with the native strain or increased expression of factor H binding protein variant 1 or 2; and vi) stabilized increased expression of Opc and PorA proteins.
Patent NZ-590022-A (NZ)
Title: An abrasive flap wheel with the flaps having a shaped side profile that varies in phase from flap to flap
Inventor: BOGALO ADRIAN GEORGE
IPC: B24D7/00
Filed: 2010-12-17
Abstract: An abrasive flap wheel (10) is disclosed. The side of the wheel (10 is profiled to minimise marks left on a work piece. The wheel (10) has a hub (20) with abrasive flaps (30) attached around it, the flap length extending outwardly from the hub (20). Each flap (30) has an edge profile so that the distance between the edge of the flap (30) and a longitudinal axis of the flap (30) varies along the length of the flap (30) from its tip towards the hub (20). The edge profile of one flap (30) is out of phase with the edge profile of the next flap so that the edge position of the flaps varies around the circumference of the wheel (10).
Patent NZ-590239-A (NZ)
Title: Picture hanging apparatus comprising a housing, at least one pair of opposing arms and a support portion
Inventor: SHORT GARRY ANDREW
IPC: A47F7/14
Filed: 2010-12-24
Abstract: An apparatus (1) for hanging a framed picture is disclosed. The apparatus (1) allows for the adjustment of height and level of the picture. The apparatus (1) comprises a housing (2) having a channel (2c) and at least one first engagement surface (2d) positioned along a surface of the housing (2) adjacent the channel (2c). There is at least one pair of opposing arms (3) configured to be biased from each other and comprising at least one second engagement surface (3b) that is movable longitudinally within the channel (2c). There is a support portion (4) that is configured to support an edge of the picture frame. The second engagement surface (3b) is configured to engage with the first engagement surface (2d). When the housing (2) has been fixed to the support surface such as wall, the vertical height of the framed picture can be adjusted by adjusting the at least one pair of opposing arms (3) relative to the housing (2).
Patent NZ-596880-A (NZ)
Title: Production of polio virus at high titers for vaccine production
Inventor: LEWIS JOHN ALFRED
IPC: A61K39/13
Filed: 2010-07-08
Abstract: 596880 Disclosed is a process for the production of poliovirus, comprising the steps of: a) providing a serum-free suspension culture of cells, which are PER.C6 cells as deposited under ECACC no. 96022940, b) infecting said cells with poliovirus, at a cell density of between 2x106 cells/ml and 150x106 cells/ml, and c) harvesting poliovirus at a time of between 12 and 48 hours after infection.
Patent NZ-597554-A (NZ)
Title: Selective glucagon-like-peptide-2 (glp-2) analogues
Inventor: LARSEN BJARNE DUE
IPC: C07K14/605
Filed: 2007-11-08
Abstract: 597554 Disclosed is a glucagon-like peptide 2 (GLP-2) analogue represented by the general formula: R1-Z1-His-Gly-Glu-Gly-Ser-Phe-Ser-Asp-Glu-Leu-X11-Thr-Ile-Leu-Glu-X16-Leu-Ala-Ala- X20-Asp-Phe-Ile-X24-Trp-Leu-IIe-X28-Thr-Lys-Ile-Thr-Asp-Z2-R2, wherein: R1 is hydrogen, C1-4 alkyl, acetyl, formyl, benzoyl or trifluoroacetyl; X11 is Leu or Phe; X16 is Leu or Phe; X20 is Ala or Ser; X24 is Ala or Ser; X28 is Ala or Ser; R2 is NH2 or OH; and Z1 and Z2 are independently absent or a peptide sequence of 1-10 amino acid units selected from the group consisting of Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp, Glu, Lys, Arg, His, Met and Orn; or a pharmaceutically acceptable salt thereof, such as: HGEGSFSDELLTILELLAASDFISWLISTKITDKKKKKK; or HGEGSFSDELFTILEFLAASDFISWLISTKITDKKKKKK; or HGEGSFSDELLTILELLAASDFISWLISTKITD; or HGEGSFSDELFTILEFLAASDFISWLISTKITD; or HGEGSFSDELLTILELLAAADFIAWLIATKITDKKKKKK.
Patent NZ-598334-A (NZ)
Title: Drive device for the cover of a liquid container
Inventor: SCHWERZMANN ARTHUR
IPC: E04H4/08
Filed: 2010-09-13
Abstract: 598334 A drive device (1) for a pool cover (10) is disclosed. The drive device (1) is disposed in a space that is separate from the liquid container (2) and is coupled to the flexible cover. At least one winding shaft (11) is coupled to a first drive unit (110) to wind up the cover (10) which is guided over a deflection device (14) to an outlet opening. The deflection device (14) comprises a pivotally mounted arm which is used to guide the cover (10) onto the winding shaft (11). The cover (10) is connected to an outer tensionable tractive element (12) which presses the cover under tension against the deflection device (14).
Patent NZ-599218-A (NZ)
Title: Process for the manufacture of organic compounds
Inventor: SEDELMEIER GOTTFRIED
IPC: C07C253/30
Filed: 2010-10-25
Abstract: 599218 Disclosed is a process for the preparation of valsartan (formula (I)). Valsartan, is (S)-N-(1-carboxy-2-methylprop-1-yl)-N-pentanoyl-N-[2’-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]amine, is an angiotensin II receptor antagonists useful in the treatment of hypertension. The process of preparing valsartan involves reaction with orangoaluminium halide and can either be a one pot synthesis or comprise the isolation of intermediates.
Patent NZ-600827-A (NZ)
Title: Granulated aromatic plant products and method for making the same
Inventor: LIAN HWEE PENG REBECCA
IPC: A23L27/10
Filed: 2010-11-09
Abstract: Disclosed is a granulated aromatic plant product composed of aromatic plants and osmotic agent, wherein said aromatic plants account for at least 0.5 w/w% dry matter up to 48 w/w% dry matter of the product and are encapsulated in the said osmotic agent, and said product having a granulated form, wherein the product has a granule size of 1.2 mm to 3.5 mm, and wherein said osmotic agent is sodium chloride or MSG or a mixture thereof.
Patent NZ-601794-A (NZ)
Title: Di - substituted pyridine derivatives as anticancers
Inventor: TAKASU HIDEKI
IPC: C07D401/12
Filed: 2011-01-28
Abstract: 601794 Disclosed are ({ 5-[Benzyloxy]pyridin-2-yl} oxy)benzene derivatives as represented by the general formula (1), wherein R1 and R2 are each independently aryl or unsaturated heterocyclic ring, each of which is optionally substituted with one or more substituents; A is alkylene; Ring X is an optionally substituted arylene; E is bond or alkenylene; ring Y is an optionally substituted heterocycloalkylene containing one or more nitrogen atoms, one of which is attached to the adjacent carbonyl group; G is -NH-G2-, -N(alkyl)-G2-, -NH-CH2-G2-, -N(alkyl)-CH2-G2- or -CH2-G2-; wherein G2 of said G binds to R2; G2 is bond, phenylene-G3-, phenylene-G4-O-, phenylene-G5-NH-, phenylene-G6-N(alkyl)- or quinolinediyl-O-, wherein the phenylene of said phenylene-G3-, phenylene-G4-O-, phenylene-G5-NH- and phenylene-G6-N(alkyl)- is optionally substituted with one or more substituents selected from the group consisting of halogen and lower alkyl; G3 is bond, -O-alkylene-, alkylene-O-alkylene- or -O-alkylene-CO-; G4 is a bond, alkylene, alkenylene, -O-alkylene or -CO-alkylene-; and G5 and G6 are each alkylene. Representative compounds include (2E)-3-[4-({ 5-[(4-methoxybenzyl)oxy]pyridin-2-yl} oxy)-3,5-dimethylphenyl]-1-(4-{ 4-[(1E)-3-(4-methylphenoxy)prop-1-en-1-yl]benzyl} piperazin-1-yl)prop-2-en-1-one, (E)-3-[3-chloro-5-methyl-4-({ 5-[(4-methylbenzyl)oxy]pyridin-2-yl} oxy)phenyl]-1-[4-(4-{ 2-[4-(propan-2-yl)phenoxy]ethyl} benzyl)-1,4-diazepan-1-yl]prop-2-en-1-one, (E)-1-[4-(4-{ 2-[(4-chlorobenzyl)oxy]ethyl} benzyl)piperazin-1-yl]-3-(3,5-dimethyl-4-{ [5-(pyridin-4-ylmethoxy)pyridin-2-yl]oxy} phenyl)prop-2-en-1-one, (E)-3-[3-chloro-5-methyl-4-({ 5-[(4-methylbenzyl)oxy]pyridin-2-yl} oxy)phenyl]-2-methyl-1-(4-{ 4-[2-(4-methylphenoxy)ethyl]benzyl} piperazin-1-yl)prop-2-en-1-one hydrochloride, 4-({ [6-(2-fluoro-4-{ (E)-3-oxo-3-[4-(4-{ 2-[4-(propan-2-yl)phenoxy]ethyl} benzyl)piperazin-1-yl]prop-1-en-1-yl} phenoxy)pyridin-3-yl]oxy} methyl)benzonitrile hydrochloride and (E)-3-[3-chloro-5-methyl-4-({ 5-[(4-methylbenzyl)oxy]pyridin-2-yl} oxy)phenyl]-1-(4-{ 4-[2-(4-fluorophenoxy)ethyl]benzyl} piperazin-1-yl)but-2-en-1-one ethanedioate. Further disclosed is a pharmaceutical composition which comprises a compound represented by the general formula (1) or a salt thereof as defined above, and a pharmacologically acceptable carrier, for preventing and/or treating cancer.
Patent NZ-604890-A (NZ)
Title: New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
Inventor: JEAN-LUC RENAUD
IPC: C07D223/16
Filed: 2012-12-19
Abstract: 604890 Disclosed herein is a process for the preparation of ivabradine of formula (I) comprising a reductive amination of the aldehyde of formula (V) with the amine of formula (VI) in the presence of formic acid, in an amount greater than 1 equivalent per equivalent of aldehyde, a dntriethylamine, in an amount greater than 1 equivalent per equivalent of aldehyde, at a temperature from 10C to 100C in the absence of solvent, or in an alcoholic solvent. Preferably wherein 2 to 50 equivalents of formic acid per equivalent of aldehyde is used, 2 to 50 equivalents of triethylamine per equivalent of aldehyde is used, and the temperature of the reaction is from 40C to 100C.
Patent NZ-614874-A (NZ)
Title: Method for isolating osteopontin using concentrated feeds
Inventor: BERTELSEN HANS
IPC: C07K14/52
Filed: 2012-03-05
Abstract: Disclosed is a method for isolating osteopontin from a milk-derived feed, the method comprising the steps of: a) providing a milk-derived feed comprising osteopontin, said milk derived feed having a pH in the range of pH 3.6-6.5 at 25 degrees C and a specific conductance in the range of 4-10 mS/cm at 25 degrees C, and wherein the milk-derived feed comprises a total amount of protein in the range of 50-250 g/L milk-derived feed, b) subjecting said milk-derived feed to anion exchange chromatography, which includes contacting the milk-derived feed with an anion exchange medium, c) optionally, washing the anion exchange medium, and d) recovering the protein bound to the anion exchange medium, thereby obtaining a composition comprising isolated osteopontin. Reference has been directed, in pursuance of Section 16(1) of the Patents Act 1953, to NZ 614872.